Historical brief · 2026-11-16

Novo’s CagriSema drives more than 20% weight loss at lower doses

Novo Nordisk presented new data at ObesityWeek showing that lower doses of its next-gen obesity drug CagriSema achieved over 20% weight loss in a Phase 3 trial. This development helps rebuild confidence as the company awaits a crucial FDA decision by the end of the year, following earlier investor disappointments.

Source image · BioSpace Drug Development

Clinical Trial Results

Novo Nordisk reported data from the Phase 3 REDEFINE 9 trial at the ObesityWeek 2026 conference. Patients receiving weekly doses of 1 mg and 1.7 mg of CagriSema lost 21% and 20.7% of their body weight, respectively, at week 68. These findings demonstrate that meaningful efficacy can be achieved below the previously studied highest dose.

Background and Market Context

CagriSema combines the amylin analog cagrilintide and the GLP-1 receptor agonist semaglutide. Earlier data from the REDEFINE 1 trial showed 22.7% weight loss at higher doses, which initially disappointed investors who had expected even higher figures. Despite previous setbacks, including failing to beat Eli Lilly’s Zepbound in a head-to-head test, Novo Nordisk continues to position the drug as a major next-generation therapy.

Regulatory Outlook and Tolerability

The latest findings form part of a broader data presentation as the drug awaits a U.S. FDA decision expected by the end of 2026. Analysts noted that tolerability remained consistent with previous studies, showing common side effects such as nausea and vomiting, while the company prepares to leverage its extensive clinical data to enter the market.

View selection rationale
Media reportStage not established

Importance 83/100

Signal80Structure85Consequence85Confidence85Momentum88
About this brief
Content type
News summary
Source type
Publisher report
Source published
Process
AI-assisted discovery, translation, summarisation, classification and scoring; standards and corrections are maintained by the editorial desk.
Verification
The original URL and publication metadata are retained. This brief is not independently fact-checked unless explicitly stated.
Published by
Polyemergence Editorial Desk · PolyEmergence Pte Ltd.
Conflict disclosure
No financial or commercial conflict declared.

Editorial standards → · Corrections →

POLYEMERGENCE / EXPLORE

Keep exploring

Follow the topic, not just the headline.

Explore the Biotech & Programmable Life archive →